Scholar Rock resubmits EMA filing while Scholar Rock stock trades at EUR 34.75

Published on 10/15/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Scholar Rock stock costs EUR 34.75 on October 15, 2026 at Lang & Schwarz. Q2 2026 GAAP net loss reached USD 109.9 million, while cash was USD 492.1 million.

Regulatory filing and valuation

Scholar Rock resubmitted its European application on October 8, 2026.
Truist kept a USD 77.00 target in its October 13, 2026 report.
Scholar Rock stock traded at EUR 34.75 at 1:34 p.m. CEST at Lang & Schwarz on October 15, 2026.

SRRK, US80706P1030, Illustration mit AI erstellt.

Scholar Rock stock was trading at EUR 34.75 at Lang & Schwarz on October 15, 2026 at 1:34 p.m. CEST, while the company advanced its European regulatory filing for apitegromab. The October 8 resubmission moves the SMA treatment back before the European Medicines Agency after a manufacturing change, according to Scholar Rock.

EMA filing resets the next milestone

The application covers apitegromab for children and adults with spinal muscular atrophy. Scholar Rock said the resubmission followed a switch to an alternate fill-finish facility that had received recent regulatory approvals, giving the European review a concrete operational context.

Analyst targets remain above the quote

Truist Securities reiterated a Buy rating and a USD 77.00 target after meeting management, Investing.com reported on October 13, 2026. MarketBeat said on October 9, 2026 that 17 research firms had an average 12-month target of USD 67.67, with 10 Buy ratings, four Strong Buy ratings, one Hold rating and two Sell ratings.

The latest reported quarter also shows the cost of the commercial transition. Scholar Rock posted a GAAP net loss of USD 109.9 million, or USD 0.84 per diluted share, for the quarter ended June 30, 2026, versus a USD 0.98 loss per share in the year-earlier quarter, according to MarketBeat.

What does the launch mean for cash?

Scholar Rock held USD 492.1 million in cash as of June 30, 2026, while operating cash flow for the second quarter was negative USD 70.3 million. Its current ratio was 7.02, a liquidity measure cited by Investing.com.

Three dated milestones carry figures

On August 6, 2026, Scholar Rock reported a quarterly loss of USD 0.84 per share, according to MarketBeat. On September 15, 2026, Piper Sandler raised its target from USD 60.00 to USD 75.00, the same source reported. On October 8, 2026, Scholar Rock resubmitted the EMA application for apitegromab, according to Scholar Rock.

The next reporting date

Scholar Rock's next estimated earnings date is November 12, 2026, according to Yahoo Finance.

EUR indication after the filing

Scholar Rock Holding Corporation is listed on Nasdaq and belongs to the healthcare biotechnology industry. The stock traded at EUR 34.75 at Lang & Schwarz on October 15, 2026 at 1:34 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Scholar Rock stock.